Biotech RadarJobs updated

COMPANY

Caribou Biosciences

HQ: Berkeley, CA source · cariboubio.com ↗ · West Coast

Clinical Phase 1

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company. From company website Source · Oct 12, 2026

Keywords: crispr genome-editing biopharmaceutical Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Lymphoma B Cell Lymphoma B-Cell Non-Hodgkin's Lymphoma Relapsed/Refractory Multiple Myeloma Hematologic Malignancy Relapsed/Refractory Acute Myeloid Leukemia Systemic Lupus Erythematosus Lupus Lupus Erythematosus Lupus Nephritis Acute Myeloid Leukemia Refractory CB-010 Caribou-sponsored investigational therapy CB-011 CB-012

Profile checked Oct 10, 2026

5Trials (company is sponsor)1NIH grants

Timeline

  1. Trial start Phase 1: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) source ↗
  2. Trial start Phase 1: CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia source ↗
  3. Trial start Phase 1: CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma source ↗
  4. Trial start —: Long-Term Follow-up Study source ↗
  5. Trial start Phase 1: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT05332054Long-Term Follow-up StudyNot listedEnrolling by invitationMar 16, 20222041-12 (estimated)
NCT05722418CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaPhase 1RecruitingFeb 6, 20232027-12 (estimated)
NCT06752876CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)Phase 1Withdrawn2027-122029-04 (estimated)
NCT06128044CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase 1TerminatedFeb 8, 2024May 30, 2025 (actual)
NCT04637763CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)Phase 1Unknown status (ClinicalTrials.gov)May 26, 20212025-08 (estimated)

NIH awards 1

Annual award amounts. Total $159K.

Connect

Contact page

Feedback